Lower MIC90 values provide powerful in vitro potency, even against pathogens of greater concern2
ARMOR Surveillance Study, 10-year Update: In vitro MIC90 (μg/mL) values for ocular bacterial isolates2*†‡
†Data are not intended to demonstrate clinical efficacy. In addition, the selected antibiotics have not been compared in head-to-head studies.
‡Asbell PA, et al. JAMA Ophthalmol. 2020;138(5):439-450.
§The number of isolates tested against gatifloxacin were MRSA, 687; MRConS, 795; S pneumoniae, 515; P aeruginosa, 667; and H influenzae, 707.
Table only includes antibiotics that are available in topical ophthalmic products with a bacterial conjunctivitis indication.
ARMOR, Antibiotic Resistance Monitoring in Ocular Microorganisms; CoNS, coagulase-negative staphylococci; H influenzae, Haemophilus influenzae; MIC90, the minimum inhibitory concentration that inhibits the growth of 90% of indicated isolates; MRCoNS, methicillin-resistant CoNS; MRSA, methicillin-resistant Staphylococcus aureus; P aeruginosa, Pseudomonas aeruginosa; S pneumoniae, Streptococcus pneumoniae.
ARMOR surveillance study limitations2
Participating sites in the United States were invited to submit a prespecified number of isolates of S aureus, CoNS, S pneumoniae, H influenzae and P aeruginosa cultured from eye infections. There is potential for sampling bias due to the infrequent practice of culturing bacterial pathogens. The application of system breakpoints to define susceptibility to ocular treatments, and thus the applicability to topically applied antibiotics, may not be relevant. Because topical antibiotics are rapidly eliminated from tears due to tear turnover, the antibiotic concentration in ocular tissue may not be indicative of the actual concentration effect.
BESIVANCE: Dual targeting activity helps increase bactericidal potency while decreasing drug resistance1-3
*Clinical significance of these in vitro data has not been established.
llIn vitro resistance to besifloxacin occurs at a general frequency of <3.3 × 10-10 for S aureus and <7 × 10-10 for S pneumoniae.3
Indication
BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.
Important Safety Information
- BESIVANCE is not for injection into the eye.
- As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
- Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
- The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
- Safety and effectiveness in infants below one year of age have not been established.
Click here for full Prescribing Information for BESIVANCE.
References: 1. Mah FS, Sanfilippo SM. Besifloxacin: efficacy and safety in treatment and prevention of ocular bacterial infections. Ophthalmol Ther. 2016;5(1):1-20. doi:10.1007/s40123-016-0046-6 2. Asbell PA, Sanfilippo CM, Sahm DF, DeCory HH. Trends in antibiotic resistance among ocular microorganisms in the United States from 2009 to 2018. JAMA Ophthalmol. 2020;138(5):439-450. doi:10.1001/jamaophthalmol.2020.0155 3. BESIVANCE [package insert]. Bridgewater, NJ: Bausch & Lomb Incorporated; 2020.
Indication
BESIVANCE® (besifloxacin ophthalmic suspension) 0.6% is a quinolone antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following bacteria: Aerococcus viridans*, CDC coryneform group G, Corynebacterium pseudodiphtheriticum*, Corynebacterium striatum*, Haemophilus influenzae, Moraxella catarrhalis*, Moraxella lacunata*, Pseudomonas aeruginosa*, Staphylococcus aureus, Staphylococcus epidermidis, Staphylococcus hominis*, Staphylococcus lugdunensis*, Staphylococcus warneri*, Streptococcus mitis group, Streptococcus oralis, Streptococcus pneumoniae, Streptococcus salivarius*
*Efficacy for this organism was studied in fewer than 10 infections.
Important Safety Information
- BESIVANCE is not for injection into the eye.
- As with other anti-infectives, prolonged use of BESIVANCE may result in overgrowth of non-susceptible organisms, including fungi. If super-infection occurs, discontinue use and institute alternative therapy.
- Patients should not wear contact lenses if they have signs or symptoms of bacterial conjunctivitis or during the course of therapy with BESIVANCE.
- The most common adverse event reported in approximately 2% of patients treated with BESIVANCE was conjunctival redness. Other adverse events reported in patients receiving BESIVANCE occurring in approximately 1-2% of patients included: blurred vision, eye pain, eye irritation, eye pruritus and headache.
- Safety and effectiveness in infants below one year of age have not been established.
Click here for full Prescribing Information for BESIVANCE.
THIS WEBSITE IS INTENDED FOR U.S. HEALTHCARE PROFESSIONALS ONLY.
Please choose an option below: